



## **Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009**

December 8, 2008

ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 8, 2008--Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the J.P. Morgan 27<sup>th</sup> Annual Healthcare Conference scheduled for Wednesday January 14, 2009 at 8:30 am Pacific. A member of the company's senior management team will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

A webcast of this presentation will be available both live and by replay. To access either the live or archived webcast, please proceed to [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com), and click on the "Investors" link the day of the presentation.

An archived replay of the webcast will be available 24 hours after the live presentation.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission--to protect life. Emergent develops, manufactures and commercializes immune-related biologics, vaccines and biotherapeutics that assist the body's immune system to prevent or treat infectious and other life threatening diseases. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's clinical pipeline includes programs focused on anthrax, botulism, typhoid, tuberculosis, hepatitis B and chlamydia. [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

CONTACT: Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows

Vice President, Investor Relations

301-795-1877

[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

or

Media Contact:

Tracey Schmitt

Director, Corporate Communications

301-795-1800

[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)

Source: Emergent BioSolutions Inc.